Name | h-arg-gly-glu-ser-oh |
---|---|
Synonyms |
ARG-GLY-GLU-SER
rgespeptide R-G-E-S |
Description | Arg-Gly-Glu-Ser is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to activated platelets. |
---|---|
Related Catalog | |
In Vivo | Arg-Gly-Glu-Ser (5 mg/kg) in combination with LPS or saline + RGDS does not affect neutrophil and macrophage cell numbers and has no effect on protein accumulation compared with LPS- or saline-treated mice, respectively[1]. |
Animal Admin | Mice[1] Mouse pharyngeal aspiration is performed in the assay. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with RGDS or Arg-Gly-Glu-Ser peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered RGDS or Arg-Gly-Glu-Ser peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS[1]. |
References |
Density | 1.61g/cm3 |
---|---|
Molecular Formula | C16H29N7O8 |
Molecular Weight | 447.44400 |
Exact Mass | 447.20800 |
PSA | 270.05000 |
Index of Refraction | 1.649 |
Storage condition | 2-8℃ |
WGK Germany | 3 |
---|